Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melany Raedy

Neurology Galion, OH Doctor of Osteopathy

NPI 1568501922 CMS profile 1299376

269 Portland Way S, Galion, OH 44833

Open in the dashboard

General payments

$7,473

559 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melany Raedy of Galion, OH is reported in the CMS Open Payments database as having received $7,473 across 559 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,355 99
2024 General $1,684 97
2023 General $1,392 88
2022 General $1,247 111
2021 General $998 88
2020 General $316 42
2019 General $480 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melany Raedy
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Melany Raedy were reported at $1,355. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Melany Raedy Neurology median Middle half National median
2019 $480 $474 $118–$2,177 $163
2020 $316 $367 $82–$2,309 $114
2021 $998 $438 $104–$2,547 $132
2022 $1,247 $442 $103–$2,388 $149
2023 $1,392 $464 $119–$2,312 $160
2024 $1,684 $468 $119–$2,323 $164
2025 $1,355 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,671 182 payments
  2. Pfizer Inc. $777 58 payments
  3. Teva Pharmaceuticals USA, Inc. $727 101 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $371 42 payments
  5. SK Life Science, Inc. $353 16 payments
  6. Amgen Inc. $329 14 payments
  7. Biohaven Pharmaceuticals, Inc. $325 29 payments
  8. Novartis Pharmaceuticals Corporation $218 12 payments
  9. Upsher-Smith Laboratories LLC $216 10 payments
  10. Supernus Pharmaceuticals, Inc. $192 19 payments
  11. Other $1,294 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,444 556 payments
  2. Education $30 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $2,024 140 payments
  2. QULIPTA $1,696 125 payments
  3. NURTEC ODT Primary Care $695 71 payments
  4. NURTEC ODT Pain $641 57 payments
  5. ZAVZPRET $586 37 payments
  6. AJOVY $531 83 payments
  7. AIMOVIG $356 16 payments
  8. ZEMBRACE SYMTOUCH $199 9 payments
  9. TROKENDI XR $192 19 payments
  10. LEQVIO $191 10 payments
  11. Other $2,152 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

2,720

Median for Neurology: 833

Drug cost

$830,367

Median for Neurology: $202,670

Branded share of claims

39.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 162 $236,002
Nurtec Odt Rimegepant Sulfate Brand 187 $204,670
Emgality Pen Galcanezumab-Gnlm Brand 136 $107,262
Qulipta Atogepant Brand 50 $75,210
Aimovig Autoinjector Erenumab-Aooe Brand 67 $55,052
Trokendi Xr Topiramate Brand 11 $28,803
Sumatriptan Succinate Generic 125 $25,252
Ajovy Autoinjector Fremanezumab-Vfrm Brand 30 $21,809
Topiramate Er Topiramate Brand 30 $17,749
Nayzilam Midazolam Brand 17 $11,927

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$3,669

Medicare's payments for the services billed

Medicare patients

34

Average age 64

Services billed

68

15 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 50%
Depression 35%
Diabetes 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$429 162 —
QULIPTA
$365 50 —
ZAVZPRET
$190 — —
BRIXADI
$119 — —
NURTEC ODT
$108 187 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record